Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 30 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2020.
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results (as of Jan 2017) assessing outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.